Background: Lower urinary tract transitional cell carcinoma (TCC) is an important but rarely described disease of cats.
| INTRODUCTION
The urinary bladder is the most common site of urinary tract neoplasia in dogs and the second most common site of urinary tract neoplasia in cats (after renal lymphoma). 1, 2 Transitional cell carcinoma (TCC) is the most prevalent lower urinary tract cancer in dogs, and considerable information regarding TCC is available for dogs, including common anatomical locations of the tumor, risk factors, treatment, and prognosis. [3] [4] [5] [6] [7] [8] [9] Many treatment modalities have been described for dogs with TCC. 3, [10] [11] [12] When surgery is performed as part of treatment, complete excision of lower urinary tract TCC lesions frequently is not achieved in dogs because of trigonal or urethral location of the tumor or both, "field effect" in which the entire urothelium undergoes malignant transformation and metastatic disease. 3 Systemic medical treatment is considered to be a mainstay of treatment in dogs with TCC and typically involves chemotherapy and cyclooxygenase (COX) inhibitors. 3, 10 Radiation therapy (with multiple protocols described) has been utilized to treat TCC in dogs, but results still are reported uncommonly. 3, 11, 12 Prognosis for dogs with TCC is strongly associated with the tumor-node-metastasis (TNM) stage at the time of diagnosis. 3 In contrast to TCC in dogs, the incidence of TCC in cats is very low and few studies have been published. 13 The largest retrospective study on TCC in cats to date documented 20 cases. 14 Four of the 20 cats had evidence of metastasis at the time of diagnosis, and treatments pursued included piroxicam administration, chemotherapy, and surgical excision. 14 The median survival time for all cats was 261 days, and 25% of cats were lost to follow-up. 14 Because of an insufficient number of cats that received any given treatment protocol, it was not possible to determine a survival advantage for any specific treatment or combinations of treatments. 14 In addition, risk factors and prognostic indicators could not be identified because of the small sample size of the study. 14 Our objectives were to report the clinical characteristics, treatments, and outcomes in a cohort of cats with TCC of the lower urinary tract and to test identified variables for prognostic relevance. We hypothesized that cats undergoing partial cystectomy as part of the treatment regimen would have an improved prognosis compared to cats that did not undergo partial cystectomy.
| MATERIALS AND METHODS

| Case selection criteria
A retrospective study was performed. The medical record databases of 11 referral veterinary clinics (9 academic teaching hospitals and 2 private practice hospitals) were searched to identify cats with lower urinary tract carcinoma that were presented to clinicians of various specialty disciplines. To be included, cats were required to have cytological or histopathological confirmation of carcinoma from a mass in either the bladder or urethra.
| Medical records review
Variables obtained from the medical records included signalment, history of lower urinary tract disease, clinical signs and duration of clinical signs, physical examination findings, clinical pathology and urine culture results, diagnostic imaging results, treatments pursued (surgery, nonsteroidal anti-inflammatory drugs (NSAIDs), chemotherapy, radiation therapy, and urethral or ureteral stent placement), documented complications and adverse events, cytology and histopathology results, progression (ie, growth of primary tumor or recurrence) of disease, documentation of metastatic disease, and timing and cause of death. Complications were considered major if they required intensive care, revision surgery, or both; all other complications were considered minor.
| Statistical analysis
Descriptive statistics were calculated, using tests of skewness and kurtosis to evaluate normal distribution for continuous variables. Multivariable logistic regression was used to model risk factors associated with receiving no treatment. Univariable analyses were performed first and variables with P < .2 were tested in the final model. Variables were retained in the multivariable model if P < .05 or if incorporation changed odds ratios (OR) by >15%. The Kaplan-Meier product limit method was used to estimate median progression-free survival (time from initial presentation to the study institution until the first instance of documented progression, regional or distant metastasis, or death) and overall survival (time from initial presentation to the study institution until death). Cats that did not reach these endpoints or were lost to follow-up were censored in the respective analyses. Log rank test for trend across ordered groups was used to compare unadjusted survival across the following treatment groups: no treatment, treatment that did not include partial cystectomy, and treatment that included partial cystectomy. Multivariable 
| Diagnostic results
Clinicopathologic results (CBC and serum biochemistry panel) were available for 102 cats at initial evaluation by the contributing clinic; Based on imaging, cytology, and histopathology results, 15 of 118 (12.7%) cats were considered to have metastatic disease at initial evaluation; 9 of 118 (7.6%) cats had metastasis to regional lymph nodes alone, 3 of 118 cats (2.5%) had abdominal carcinomatosis, 1 cat had metastasis to a regional lymph node and omental tissue near the bladder, 1 cat had presumed pulmonary metastasis based on thoracic radiographs, and 1 cat had both regional lymph node and presumed pulmonary metastasis based on thoracic radiographs. Cases of nonpulmonary metastasis were confirmed by cytology or histopathology, whereas cases of pulmonary metastasis were reported as suspected based on radiographic interpretation by a board-certified radiologist.
| Treatment
Information regarding treatment (specifically cystectomy) is found in Numbers refer to number (percentage) of cats. Nearly 2/3 of cats received treatment and 38% of those that received treatment underwent partial cystectomy. Although many locations of the bladder were excised, the ventral wall and apex were most common. 
| DISCUSSION
To date, information on prognosis and recommended treatments for cats with TCC of the lower urinary tract has been limited because of a lack of data. Our results demonstrate the importance of treatment with cystectomy and NSAIDs in cats with TCC. Our findings highlight several important differences between dogs and cats with TCC, including tumor location, treatment modalities with the greatest effect on outcome, disease progression, and prognosis.
Many of the cats in our study had a history of lower urinary tract disease, and the majority of cats (92/118; 78.0%) were evaluated by veterinarians for urinary tract signs or disease before diagnosis. It is possible that the diagnosis of TCC and subsequent treatment may have been delayed in many of these cats because of the lack of inclusion of TCC as a differential diagnosis. Alternatively, prior lower urinary tract disease and inflammation may have predisposed these cats to the development of TCC. Nevertheless, these findings emphasize the importance of diagnostic testing to evaluate for potential neoplasia of the lower urinary tract even in cats with a history of other common forms of lower urinary disease, particularly when signs are recurrent or refractory to treatment.
Location of TCC appears to be more variable in cats than in dogs,
but the trigone appears to be the most common location for occurrence in both species. Whereas trigonal disease is reported in the majority of dogs with TCC, we found trigonal disease in only 32 of 118 (27.1%) cats with TCC. 5 Although TCC in both dogs and cats is typically invasive in nature (similar to high-grade, invasive TCC in humans), relative to tumor location, TCC in cats may be a better model for TCC in humans because this neoplasm affects the trigone in only 23% of human patients with urinary bladder TCC. 8, 15 Thus, the treatment limitations associated with trigonal location of TCC in dogs F I G U R E 1 Kaplan-Meier estimates of survival with different treatment groups. Survival increased significantly (P < .001) when comparing cats across the ordered treatment groups: no treatment, treatment without partial cystectomy, treatment with partial cystectomy may not be as applicable in the treatment of this disease in cats and humans. Importantly, when TCC was located in the trigone of cats in our study, these cats were less likely to receive treatment. This finding supports the influence of location of TCC on treatments pursued and overall outcomes in these cats, because receiving no treatment was associated with significantly shorter survival.
The potential for seeding TCC within the abdomen or body wall after FNA or biopsy of the tumor as well as peritoneal surgery has been well documented in dogs with TCC. 3, 4, 9, [16] [17] [18] One cat in our study developed potential extension of TCC into the ventral body wall after FNA, and 3 of 118 (2.5%) cats developed abdominal carcinomatosis after FNA (2/3; 66.7%) or celiotomy with urinary surgery (1/3; 33.3%). Therefore, as with TCC in dogs, it is important to consider the potential for neoplastic seeding after tumor sampling (FNA or biopsy) or laparotomy with urinary tract surgery in cats with lower urinary tract TCC. However, given the limited number of cats that developed this complication in our study as well as the relatively poor survival times for cats with TCC, ultimately obtaining a diagnosis and providing treatment generally should be pursued, after careful consultation with owners, in an effort to improve the outcomes of affected cats.
The role of surgery in the treatment of dogs with TCC generally has been considered limited because of the typical trigonal location, high frequency of urethral involvement, and commonly documented metastatic disease at the time of diagnosis. 5, 9 However, a recent study on outcomes in 37 dogs that underwent partial cystectomy with or without other nonsurgical treatments for TCC found relatively improved outcomes, despite attaining histopathologically incomplete excision in 60% of the cases. 19 Total cystectomy is not currently pursued in many dogs, and the management of dogs with lower urinary tract TCC often is palliative in nature with placement of urethral or ureteral stents to maintain patency of the urinary tract without directly altering tumor progression. 9 In cats with TCC in our study, partial cystectomy was associated with significantly improved survival times (when compared to cats not undergoing treatment or cats undergoing treatment not including cystectomy). Cats that underwent partial cystectomy as part of their treatment protocol experienced the longest median survival time and highest 1-and 2-year survival rates. Interestingly, however, although untreated cats had the shortest median survival time, higher 1-and 2-year survival rates were seen in this subgroup than in cats that were treated without cystectomy. We hypothesize that this finding may be attributable to a less aggressive form of disease in a small number of cats that have the potential for longer survival without treatment.
These cats may have fewer clinical signs associated with TCC and, subsequently, owners may be less inclined to treat them. However, a potential incorrect diagnosis of TCC in such cats cannot be ruled out.
A relatively large proportion of cats in our study (28/118; 23 .7%) underwent partial cystectomy; no cats underwent radical cystectomy.
Partial cystectomy was performed in only 2 cats with trigonal disease.
Although the postoperative complication rate was relatively low (6/28; 21.4%), 3 of 6 (50.0%) of the complications were considered major, and both cats with trigonal tumors that underwent partial cystectomy developed major complications. Given the potential for major complications after cystectomy in cats with trigonal disease, the possible role of surgery in these patients should be further investigated with additional studies because of the small sample size of cats with trigonal tumors that underwent partial cystectomy in our study. Importantly, 14 of 22 (63.6%) cats that underwent partial cystectomy developed recurrence of TCC, and recurrence was seen in a large proportion (4/9; 44.4%) of cats that reportedly had completely excised TCC. Overall, however, our data suggests that partial cystectomy can be considered a viable treatment option in cats with TCC, and this surgical procedure can result in improved outcomes for these patients. Additional studies are required to determine the role of radical cystectomy on outcomes in cats with TCC. teral obstruction secondary to TCC should be considered in an effort to provide palliation for obstructive local disease. 23, 24 Radiation therapy has been utilized infrequently in the treatment of TCC in dogs, and this appears to be similar in cats as evidenced by only 3 of 118 (2.5%) cats in our study undergoing radiation therapy. 11, 12 The radiation therapy protocols used in the cats of our study all were hypofractionated and palliative in intent. Additional studies are needed to further determine the role of radiation therapy and optimal protocols for its use in the treatment of both dogs and cats with lower urinary tract TCC.
In dogs, systemic medical treatments including chemotherapy agents and COX inhibitors are considered to be mainstay treatments for TCC. 3, 8, 9 Multimodal medical therapy has been shown to improve response rates and survival times in dogs with TCC. 10, 25, 26 In our study, appropriately and should be considered as part of the treatment strategy whenever possible for cats with TCC. However, given the retrospective nature of our study, the frequency or severity of adverse events may have been underreported, and thorough discussion of possible adverse events with clients is indicated before long-term use of NSAIDs in cats.
Although chemotherapy and other treatment modalities ultimately may play a role in treatment of cats with TCC, our findings suggest that surgical excision and NSAID administration should be the primary recommended treatments in cats with lower urinary tract TCC in an effort to improve outcomes. However, these treatments will not be possible or appropriate in all cats with lower urinary tract TCC, and any treatment (relative to no treatment) may result in an improved outcome for affected cats.
Overall, the prognosis for cats with lower urinary tract TCC is guarded. 14, 32 This finding points to a need for improvement in our management of these patients. Whereas the overall frequency of metastatic disease in cats with TCC was at least 25 of 118 (21.2%), the frequency of documented tumor progression was 45 of 81 (55.6%), with frequency of recurrence after cystectomy was 14 of 22 (63.6%).
The relatively higher rate of tumor progression emphasizes the need to improve local control of this disease. Additional studies regarding radical cystectomy and radiation therapy in cats with TCC are needed to further determine the role of these treatments on local disease control and overall outcomes in cats with TCC.
Our study had several limitations. First, the study was retrospective with resultant potential for incomplete clinical information for some patients. Many cases were lost to follow-up, which can lead to underinterpretation or overinterpretation of many findings, including documentation of metastasis and response to treatment. Because of wide variability in patient, disease, treatment, and outcome information, valid comparisons of outcomes across subgroups of cats could not be made. For example, it was not possible to make assessments of the subgroup of cats with trigonal disease that underwent treatment or cats that underwent treatment with NSAIDs and partial cystectomy compared to NSAIDs alone and partial cystectomy alone because of small numbers of cats in these subgroups and multiple potential confounders. A second limitation is probable selection bias because academic institutions primarily contributed cases, and both patient and client factors likely influenced the type of treatment, if any, that was administered to individual cats. Additionally, prior care at referring practices was not accounted for in this data set, which could have resulted in underestimation of treatment effects or survival times.
Cats may have undergone treatment at a referring veterinary clinic that may have improved clinical signs or outcome, but no evidence of any cat undergoing NSAID administration, chemotherapy, or surgery before referral was noted. Many cats with suspected TCC were excluded because of lack of cytological or histopathological confirmation, such that the sample size likely did not include all cats with the disease. Finally, given the long inclusion period of the study, bias may have originated from changes in the recommended diagnostic and treatment modalities for these patients over time.
In conclusion, our study represents the largest report to date on cats with TCC of the lower urinary tract. This information can be used to inform clinicians and owners about this disease process in cats and to guide treatment recommendations and discussions on prognosis. Although the statistically significant findings in this study emphasize the importance of partial cystectomy and NSAID administration in cats with TCC, additional work is necessary to evaluate larger numbers of cats undergoing these and other treatments.
